論文全著者名. 論題. 雑誌名. 発行年; 巻 :始頁-終頁

著者名

Yano Y, Kurebe H, Edahiro R, Hosono Y,
Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung
Nakatsubo S, Nishida K, Sawa N, Ishijima M,
cancer: A retrospective study. PLoS One. 2018 Aug 28;13(8):e0203070. doi: 10.1371/journal.pone.0203070.
Uenami T, Kanazu M, Akazawa Y, Yamaguchi T,
eCollection 2018.
Mori M
Kanazu M, Edahiro R, Krebe H, Nishida K,
Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case
Ishijima M, Uenami T, Akazawa Y, Yano Y,series. Thorac Cancer. 2018 Dec;9(12):1782-1787. doi: 10.1111/1759-7714.12894. Epub 2018 Oct 17.
Yamaguchi T, Mori M

Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung Uenami T, Ishijima M, Kanazu M, Kurebe H,adenocarcinoma patients with programmed death-ligand 1 overexpression. Ann Transl Med. 2018 Edahiro R, Nishida K, Akazawa Y, Yano Y,
Nov;6(22):444. doi: 10.21037/atm.2018.10.24.
Yamaguchi T, Mori M
Koba T, Minami S, Nishijima-Futami Y, Masuhiro
Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed
K, Kimura H, Futami S, Yaga M, Mori M, Kagawa
maintenance for untreated non-squamous non-small-cell lung cancer. Cancer Chemother Pharmacol.
H, Uenami T, Kohmo S, Otsuka T, Yamamoto S,
2018 Jul;82(1):111-117. doi: 10.1007/s00280-018-3598-4. Epub 2018 May 4.
Komuta K, Kijima T
Uchibori K, Satouchi M, Sueoka-Aragane N,Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small
Urata Y, Sato A, Imamura F, Inoue T, Tachihara
cell lung cancer harboring EGFR gene mutations. Lung Cancer. 2018 Oct;124:65-70. doi:M, Kobayashi K, Katakami N, Kokan C, Hirashima
10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.
T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S

HANSHIN Oncology Group. Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Hata A, Katakami N, Kaji R, Yokoyama T,
Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y,2 Trial (ABC Study). Cancer. 2018 Sep 7. doi: 10.1002/cncr.31678. [Epub ahead of print]
Tamura D, Morita S, Negoro S

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell Tachihara M, Negoro S, Inoue T, Tamiya M,lung cancer patients (HANSHIN 0316). BMC Cancer. 2018 Oct 3;18(1):946. doi: 10.1186/s12885-018- Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata
4819-2.
A, Katakami N, Yokota S

Osa A, Uenami T, Koyama S, Fujimoto K,Okuzaki D, Takimoto T, Hirata H, Yano Y,
Yokota S, Kinehara Y, Naito Y, Otsuka T,
Clinical implications of monitoring nivolumab immunokinetics in non – small cell lung cancer patients Kanazu M, Kuroyama M, Hamaguchi M, Koba T,
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Futami Y, Ishijima M, Suga Y, Akazawa Y,Insight. 2018 Oct 4;3(19). pii: 59125. doi: 10.1172/jci.insight.59125. [Epub ahead of print]
Machiyama H, Iwahori K, Takamatsu H,
Nagatomo I, Takeda Y, Kida H, Akbay EA,
Hammerman PS, Wong KK, Dranoff G, Mori M,
Kijima T, Kumanogoh A

HANSHIN Oncology Group. Does afatinib plus bevacizumab combination therapy induce positive Hata A, Katakami N, Kaji R, Yokoyama T,
conversion of T790M in previously-negative patients? Oncotarget. 2018 Oct 5;9(78):34765-34771. doi: Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y,
10.18632/oncotarget.26192. eCollection 2018 Oct 5.
Tamura D, Morita S, Negoro S

Kunikane H, Yokota I, Katakami N, Takeda K,
Prospective analysis of the association between skeletal-related events and quality of life in patients withTakayama K, Sawa T, Saito H, Harada M, Yokota
advanced lung cancer (CSP-HOR13). Oncol Lett. 2019 Jan;17(1):1320-1326.
S, Ando K, Saito Y, Ohashi Y, Eguchi K.

A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Yokoi T, Minami S, Shiroyama T, Koba T, Torii Y,Squamous Cell Lung Cancer: OSAKA-LCSG 1102. Intern Med. 2019 Feb 1. doi: Sugimoto H, Niki M, Mori M, Morimura O,
10.2169/internalmedicine.1172-18. [Epub ahead of print]
Hirashima T, Komuta K, Kijima T

Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Kitagawa C, Mori M, Ichiki M, Sukoh N, Kada A,Cancer. In Vivo. 2019 Mar-Apr;33(2):477-482. doi: 10.21873/invivo.11498.
Saito AM, Ichinose Y
メディカル・トピックス「肺がん内科治療で免疫治療薬が主役になるかも？」．豊中市医師会月報 2018年7 森 雅秀